Worldwide Recall : Neuroveen, Respitrol, Thyroveev, Compulsin For Contamination – FDA

by Kim Boateng Posted on August 30th, 2018

Silver Spring, Maryland, USA: The U.S. Food and Drug Administration, FDA, said HelloLife, Inc. in Grand Rapids, MI is initiating a voluntary recall of four different products, Neuroveen, Respitrol, Thyroveev and Compulsin, within expiry, to the retail and consumer level due to possible microbial contamination. Neuroveen has been tested and found to be contaminated with Staphylococcus saprophyticus and Burkholderia cepacia. Compulsin has been identified as containing Burkholderia cepacia.

Respitrol and Thyroveev are still pending bacterial identification. Each product being recalled is for a single lot that was packaged into 2-ounce amber bottles (see table below) that were manufactured at the King Bio, Inc facility in Asheville, NC.

Administration or use of drug products with microbial contamination could potentially result in increased infections that may require medical intervention, and could result in infections that could be life threatening to certain individuals. To date, HelloLife, Inc. has not received any reports of adverse events related to the recalled products.

Specific information is as follows, all products are packaged into 2 ounce amber bottles:

PRODUCT INDICATION NDC UPC LOT EXP. DATE
Neuroveen Natural temporary relief for nerve pain symptoms 49726-
015-02
891129002804 NV/030717D 07/19
Respitrol Natural temporary relief for respiratory symptoms 49726-
003-02
891129002729 RE/030717E 07/19
Thyroveev Natural temporary relief for sluggish thyroid symptoms 49726-
025-02
349726000063 TVV/030717F 07/19
Compulsin Nervous, repetitive thought/behavior relief 49726-
034-02
891129002194 CO/030717B 07/19

These products can be identified by the main label on the bottle and the lot number that is printed on the label. Product was distributed worldwide via wholesale, retail and online sales.

HelloLife, Inc. is notifying its distributors and customers by email, phone calls and written letters sent via the postal service and is arranging for replacement products where available and/or refunds. Consumers, retailers and wholesalers that have product, which is being recalled, should stop use immediately and remove all inventory from sales and contact HelloLife, Inc. to arrange for disposal and product replacement or refunds.

Consumers with questions regarding this recall can contact HelloLife, Inc. by calling 1-616-803- 7243 Monday-Friday 9:00 a.m. to 5:00 p.m. EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting Program wither online, by regular mail or by fax. FDA contact instructions are:

  • Complete and submit the report Online: www.fda.gov/medwatch/report.htm
  • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company’s announcement as a public service. FDA does not endorse either the product or the company.

FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Author

Kim Boateng

Kim Boateng

Staff Writer
Phone
Email

Leave a Reply